Top Markets
Coin of the day
Bioceltix S.a. Bioceltix S.a.

Bioceltix S.a.

BCX
Rank in Stocks #20646
Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals... Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. The company’s products include BCX-CM-J, a stem-cell based biological drug for the treatment of osteoarthritis in dogs; BCX-CM-AD, a drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a drug candidate based on allogeneic mesenchymal stem cells for the treatment of arthritis in horses. The company was founded in 2016 and is headquartered in Wroclaw, Poland.
Share Price
$22.66
Market Cap
$125.37M
Change (1 day)
0.63%
Change (1 year)
-21.46%
Country
PL
Trade Bioceltix S.a. (BCX)

Category

P/S ratio for Bioceltix S.a. (BCX)
P/S ratio as of 2026 TTM: 0
According to Bioceltix S.a. latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0. At the end of 2026 the company had a P/S ratio of 0.
P/S ratio history for Bioceltix S.a. from 2026 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
Not enough data for the provided dates.
P/S ratio for similar companies or competitors
Company P/S Ratio P/S Ratio Difference Country
10.17 -
US
10.13 -
NL
11.28 -
US
2.95 -
AU
- -
CH